Zev Asch Speaks About Disruptive Thinking for Small Business Owners
January 11, 2022 06:25 ET
|
Mission Matters Business Podcast
Beverly Hills , Jan. 11, 2022 (GLOBE NEWSWIRE) -- Zev Asch's mission and purpose are one and the same: to change the lives of business owners by helping them grow their companies and achieve a...
Aptive Environmental Recognized On Inc.’s 2021 Best in Business List
December 07, 2021 13:46 ET
|
Aptive Environmental
PROVO, Utah, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Aptive Environmental, one of the fastest-growing pest control companies in North America, has been recognized on the Inc. 2021 Best in Business list as...
Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits
November 22, 2021 08:03 ET
|
Codex
San Diego, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, and RNAimmune, a leading biotech company with expertise in...
Way2Grow (W2G) Biopharma Corp. Receives Health Canada Approval Notice for Construction of a Controlled Substances Dealer’s Licence Level 8 Psychedelic Secure Environ and Psilocybin Production Campus
November 17, 2021 07:30 ET
|
Way2Grow Biopharma Corp.
OSOYOOS, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Way2Grow Biopharma Corp. (“W2G” or the “Company”), a privately held therapeutic corporation existing under the laws...
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
November 15, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
November 08, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC
November 04, 2021 11:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel...
For the 12th Time, Access Recognized on the Inc. 5000, With Three-Year Revenue Growth of 43 Percent
November 03, 2021 12:15 ET
|
Access
WOBURN, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it is being recognized for the...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
November 02, 2021 08:30 ET
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by...
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 02, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first...